10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

SFXN5 Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP6403b

Specification

SFXN5 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession	Q8TD22
Other Accession	NP_653180

SFXN5 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 94097

Other Names
Sideroflexin-5, SFXN5

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6403b was selected from the C-term region of human SFXN5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SFXN5 Antibody (C-term) Blocking Peptide - Protein Information

Name SFXN5 {ECO:0000303|PubMed:12039050, ECO:0000312|HGNC:HGNC:16073}

Function
Mitochondrial amino-acid transporter (By similarity). Transports citrate (By similarity). Does not act as a serine transporter: not able to mediate transport of serine into mitochondria (PubMed:30442778) (By similarity). In brown adipose tissue, plays a role in the regulation of UCP1-dependent thermogenesis probably by supporting mitochondrial glycerol-3-phosphate utilization (By similarity).

Cellular Location
Mitochondrion inner membrane; Multi-pass membrane protein

Tissue Location

Primarily expressed in the brain.

SFXN5 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

SFXN5 Antibody (C-term) Blocking Peptide - Images

SFXN5 Antibody (C-term) Blocking Peptide - Background

Parkinson's disease (PD) is a multifactorial disease that appears to arise from the effects of both genetic and environmental influences. The known genetic factors include multiple genes that have been identified in related parkinsonian syndromes, as well as alpha-synuclein. Genes associated with either PD or Parkinson-related disorders include parkin, DJ-1, ubiquitin C-terminal hydrolase isozyme L1 (UCH-L1), nuclear receptor-related factor 1 (NURR1), and alpha-synuclein. SFXN5 has been known to locate at the Park3 region of chromosome 2p (PARK3; OMIM 602404). However, sequence analysis of 2p13 linked individuals affected with PD did not reveal any potentially pathogenic mutations within SFXN5, suggesting SFXN5 may not correspond to PARK3 (Lockhart et al.). Search for Park3 gene is still under development and HtrA2 is suspected to be one candidate.

SFXN5 Antibody (C-term) Blocking Peptide - References

Lockhart,P.J., et al. Gene 285 (1-2), 229-237 (2002)Snyder H and Wolozin B. J Mol Neurosci. 24(3):425-42. Review. (2004)